title: Cutaneous macroglobulinosis treated with bortezomib and rituximab.
authors.affiliation: Department of Hematology, CHU Rennes, Hôpital Pontchaillou, Rennes, France.
authors.forename: Tony
authors.initials: T
authors.lastname: Marchand
authors.forename: Patrick
authors.initials: P
authors.lastname: Tas
authors.forename: Roch
authors.initials: R
authors.lastname: Houot
authors.forename: Charles
authors.initials: C
authors.lastname: Dauriac
authors.forename: Thierry
authors.initials: T
authors.lastname: Lamy
authors.forename: Xavier
authors.initials: X
authors.lastname: Cahu
mesh_terms: D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage*; D001897:Boronic Acids / Q000008:administration & dosage*; D000069286:Bortezomib; D006801:Humans; D007075:Immunoglobulin M / Q000378:metabolism; D008297:Male; D011719:Pyrazines / Q000008:administration & dosage*; D012008:Recurrence; D000069283:Rituximab; D012871:Skin Diseases / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D008258:Waldenstrom Macroglobulinemia / Q000276:immunology / Q000473:pathology / Q000628:therapy*
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D001897:Boronic Acids; D007075:Immunoglobulin M; D011719:Pyrazines; D000069283:Rituximab; D000069286:Bortezomib